BesicN, HocevarM, ZgajnarJ. 2010. Lower incidence of anaplastic carcinoma after higher iodination of salt in Slovenia. Thyroid, 20:623–626.
2.
LaurbergP, CerqueiraC, OvesenL, RasmussenL, PerrildH, AndersenS, PedersenI, CarléA. 2010. Iodine intake as a determinant of thyroid disorders in populations. Best Pract Res Clin Endocrinol Metab, 24:13–27.
3.
Feldt RasmussenU. 2001. Iodine and cancer. Thyroid, 11:483–486.
4.
HarachHR, CeballosGA. 2008. Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model. Endocr Pathol, 19:209–220.
5.
BurgessJR. 2002. Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma. Thyroid, 12:141–149.
6.
LiuXH, ChenGG, VlantisAC, van HasseltCA. 2009. Iodine mediated mechanisms and thyroid carcinoma. Crit Rev Clin Lab Sci, 46:302–318.
7.
EliseiR, MolinaroE, AgateL, BotticiV, MasseriniL, CeccarelliC, LippiF, GrassoL, BasoloF, BevilacquaG, MiccoliP, Di CoscioG, VittiP, PaciniF, PincheraA. 2010. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab, 95:1516–1527.
8.
FarahatiJ, GelingM, MäderU, MörtlM, LusterM, MüllerJG, FlentjeM, ReinersC. 2004. Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981–1995. Thyroid, 14:277–286.
9.
Bacher-StierC, RiccabonaG, TötschM, KemmlerG, OberaignerW, MoncayoR. 1997. Incidence and clinical characteristics of thyroid carcinoma after iodine prophylaxis in an endemic goiter country. Thyroid, 7:733–741.
10.
Gomez SegoviaI, GallowitschHJ, KresnikE, KumnigG, IgercI, MatschnigS, StroneggerWJ, LindP. 2004. Descriptive epidemiology of thyroid carcinoma in Carinthia, Austria: 1984–2001. Histopathologic features and tumor classification of 734 cases under elevated general iodination of table salt since 1990: population-based age-stratified analysis on thyroid carcinoma incidence. Thyroid, 14:277–286.
11.
UyttersprotN, PelgrimsN, CarrascoN, GervyC, MaenhautC, DumontJE, MiotF. 1997. Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroperoxidase and Na+/I− symporter mRNAs in dog thyroid. Mol Cell Endocrinol, 131:195–203.
12.
VitaleM, di MatolaT, D'AscoliF, SalzanoS, BogazziF, FenziG, MartinoE, RossiG. 2000. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology, 141:598–605.
13.
MutakuJF, PomaJF, ManyMC, DenefJF, van Den HoveMF. 2002. Cell necrosis and apoptosis are differentially regulated during goitre development and iodine-induced involution. J Endocrinol, 172:375–386.
14.
García-SolísP, AlfaroY, AnguianoB, DelgadoG, GuzmanRC, NandiS, Diaz-MunozM, Vazquez-MartinezO, AcevesC. 2005. Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I−) treatment: evidence that I2 prevents cancer promotion. Mol Cell Endocrinol, 236:49–57.
15.
GärtnerR, RankP, AnderB. 2010. The role of iodine and delta-iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. Hormones (Athens), 9:60–66.
16.
SmallridgeRC. 2010. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) Apr 23[Epub ahead of print].
17.
LiuXH, ChenGG, VlantisAC, TseGM, van HasseltCA. 2010. Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells. Mol Cell Endocrinol, 320:128–135.
18.
SurksMI, HollowellJG. 2007. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab, 92:4575–4582.
